SCHEMBL21404973

SCHEMBL21404973

CC(C)(C)OC(=O)N[C@@H](C(=O)O)c1ccc(Br)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.51
CTSK P43235 3/20 0.51
FPR2 P25090 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RECQL P46063 1/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
CYP1A2 P05177 1/20 0.44
AAK1 Q2M2I8 5/20 0.42
ATM Q13315 1/20 0.41
CACNA1B Q00975 1/20 0.41
CTSB P07858 1/20 0.40
S1PR3 Q99500 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2306924 1.00 CTSS (0.51) CTSSCTSKFPR2SMN1; SMN2NPC1
SCHEMBL24516267 1.00 CTSS (0.51) CTSSCTSKFPR2SMN1; SMN2NPC1
SCHEMBL26648342 0.88 CTSS (0.48) CTSSCTSKSMN1; SMN2NPC1RECQL
SCHEMBL3503830 0.87 CTSS (0.47) CTSSCTSKSMN1; SMN2NPC1RECQL
SCHEMBL8258359 0.87 CTSS (0.47) CTSSCTSKSMN1; SMN2NPC1RECQL
SCHEMBL191986 0.86 CTSS (0.52) CTSSCTSKATMS1PR3PPARG
SCHEMBL843924 0.86 CTSS (0.52) CTSSCTSKATMS1PR3PPARG
SCHEMBL8513252 0.86 CTSS (0.52) CTSSCTSKALDH1A1ATMCTSB
SCHEMBL12195416 0.86 CTSS (0.52) CTSSCTSKALDH1A1ATMCTSB
SCHEMBL191987 0.86 CTSS (0.52) CTSSCTSKATMS1PR3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-12 US disclosed
US-12539292-B2 BRM targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-03 US disclosed
EP-4537905-A2 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-04-16 EP disclosed
EP-3774789-B1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-03-05 EP disclosed
US-20240076295-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2024-03-07 US disclosed
EP-4038066-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2022-08-10 EP disclosed
CN-114787159-A BRM targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-07-22 CN disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 WO disclosed
EP-3774789-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 EP disclosed
CN-112166114-A BRM targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2021-01-01 CN disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 US disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 WO disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240076295-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL CTSS 3977/4885CTSK 3850/4885FPR2 3912/4885
US-12539292-B2 BRM targeting compounds and associated methods of use ADRM1, SUMO2, BAZ1A CTSS 3703/4885CTSK 4031/4885FPR2 4134/4885
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL CTSS 3977/4885CTSK 3850/4885FPR2 3912/4885
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL CTSS 3977/4885CTSK 3850/4885FPR2 3912/4885
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, VHL, BAZ1A CTSS 4183/4885CTSK 4274/4885FPR2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.